Verition Fund Management
RLAY icon

Verition Fund Management’s Relay Therapeutics RLAY Stock Holding History

Verition Fund Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-290,599
Closed -$1.01M – 3967
2025
Q2 		$1.01M Buy
290,599
+151,355
+109% +$450K ﹤0.01% 2472
2025
Q1 		$365K Buy
139,244
+48,770
+54% +$191K ﹤0.01% 2767
2024
Q4 		$373K Buy
90,474
+14,335
+19% +$78K ﹤0.01% 2652
2024
Q3 		$539K Buy
76,139
+62,320
+451% +$466K ﹤0.01% 2279
2024
Q2 		$90.1K Sell
13,819
-5,575
-29% -$38.1K ﹤0.01% 2740
2024
Q1 		$161K Buy
19,394
+3,224
+20% +$31.5K ﹤0.01% 2533
2023
Q4 		$178K Sell
16,170
-42,655
-73% -$360K ﹤0.01% 2067
2023
Q3 		$495K Buy
58,825
+24,387
+71% +$262K 0.01% 1442
2023
Q2 		$433K Buy
+34,438
New +$428K 0.01% 1317

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Verition Fund Management's RLAY Position: Q3 2025 in Review

Verition Fund Management sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 290,599 shares — an estimated $1.01M sold.

Verition Fund Management first reported a position in RLAY in Q2 2023 and held it in 9 quarters. The position peaked at $1.01M in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • Verition Fund Management reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 290,599 Relay Therapeutics shares in Q3 2025, an estimated $1.01M.
  • Verition Fund Management first reported a position in Relay Therapeutics in Q2 2023 and held it in 9 quarters.
  • Verition Fund Management's Relay Therapeutics position peaked at $1.01M in Q2 2025.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.